Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

ALAMEDA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. The augmented partnership builds on the two companies’ ongoing collaboration and license agreement to discover and develop mono-specific and multi-specific...

Click to view original post